Study of a Blood Test to Help Manage Patients During Colorectal Cancer Screening

What this Trial Is About

Colorectal cancer is one of the most common cancers in both men and women, with increasing cases each year. Early detection is vital, often starting with a stool blood test followed by a colonoscopy if positive. Due to delays in colonoscopies during the COVID-19 pandemic, researchers are exploring a blood test to quickly identify patients who need urgent care for colorectal cancer, aiming to improve treatment timing especially during times of healthcare disruption. The study involves two groups Cohort A includes 200 patients suspected of having colorectal cancer after a positive stool blood test or visible bleeding, and Cohort B includes 200 patients already diagnosed with colorectal cancer confirmed by pathology before surgery. Participants will provide blood samples before and one month after surgery, with additional stool samples collected in Cohort B. Tumor tissue from surgery will also be collected for analysis. Participants undergo blood and stool sample collections along with tumor tissue analysis to evaluate the blood tests ability to detect colorectal cancer and its correlation with disease stage. The main outcomes include measuring the blood tests sensitivity and specificity one month after surgery and around six months after inclusion. The study is sponsored by Centre Hospitalier Universitaire de Besancon and aims to enhance colorectal cancer screening and management over a long follow-up period ending in 2032.

Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening